Hyperosmolar Non-Ketotic Diabetic Coma

Definition and Diagnostic Criteria

• Hyperosmolar non-ketotic diabetic coma, currently and more accurately referred to as Hyperglycemic Hyperosmolar Syndrome (HHS) or Hyperglycemic Hyperosmolar State, is a life-threatening acute metabolic complication of diabetes mellitus.
• It is clinically characterized by a triad of extreme hyperglycemia, profound hyperosmolality, and severe systemic dehydration, occurring in the absence of significant ketoacidosis.
• The established biochemical criteria for the definitive diagnosis of HHS in pediatric and adolescent patients include all of the following parameters:
  • Plasma glucose concentration exceeding 33.3 mmol/L (600 mg/dL).
  • Venous pH greater than 7.25, or an arterial pH greater than 7.30, indicating the absence of severe acidemia.
  • Serum bicarbonate concentration greater than 15 mmol/L.
  • Absent to only small quantities of ketonemia and ketonuria.
  • An effective serum osmolality greater than 320 mOsm/kg.
• Additionally, the clinical presentation frequently requires the presence of an altered level of consciousness, manifesting as obtundation, combativeness, or frank seizures, which occur in approximately 50% of patients.

Epidemiology and Precipitating Factors

• While HHS is traditionally considered a complication of adult-onset type 2 diabetes mellitus, its incidence within the pediatric population is steadily rising in parallel with the increasing prevalence of childhood obesity and youth-onset type 2 diabetes.
• Current epidemiological data indicate that approximately 2% of youth diagnosed with type 2 diabetes present initially with HHS, and these patients are frequently affected by morbid obesity.
• A significant proportion of children who present with HHS have a high incidence of preexisting neurological injury or severe developmental delay.
• The metabolic decompensation in HHS develops insidiously over a period of days to weeks, much slower than the typical evolution of Diabetic Ketoacidosis (DKA).
• Initially, the obligatory osmotic diuresis and subsequent dehydration induced by hyperglycemia may be partially compensated for by increased fluid intake.
• The syndrome frequently accelerates when the patient consumes excessive quantities of sugar-sweetened beverages in an attempt to quench their profound thirst, paradoxically exacerbating the extreme hyperglycemia.
• With progressive hyperosmolality, the patient's thirst mechanism ultimately becomes impaired; this may be due to the direct alteration of the hypothalamic thirst center by the extreme hyperosmolar state, or secondary to a preexisting defect in the hypothalamic osmoregulating mechanism.

Pathophysiology

Mechanisms of Severe Hyperglycemia and Dehydration

• The fundamental pathophysiological difference between HHS and DKA lies in the degree of insulinopenia; while DKA features near-absolute insulin deficiency, HHS is characterized by a state of relative insulin deficiency.
• In HHS, there is sufficient residual endogenous insulin secretion to effectively suppress lipolysis in adipose tissue, thereby preventing massive free fatty acid release and subsequent hepatic ketogenesis.
• However, this residual insulin concentration is highly inadequate to suppress hepatic gluconeogenesis or to facilitate normal peripheral glucose utilization, especially in the presence of elevated stress or counterregulatory hormones (e.g., glucagon, cortisol, catecholamines).
• The unchecked hepatic glucose production combined with severely impaired peripheral clearance results in profound hyperglycemia.
• When serum glucose vastly exceeds the renal threshold, massive osmotic diuresis ensues, leading to total body fluid losses that are estimated to be twice as severe as those typically observed in DKA.

Mechanisms of Absent Ketosis

• The defining lack of significant ketosis in HHS is primarily attributed to the direct metabolic effects of hyperosmolarity itself.
• In vitro studies demonstrate that extreme hyperosmolarity directly blunts the lipolytic effect of epinephrine on adipose tissue, while simultaneously enhancing the antilipolytic effect of the small amounts of circulating residual insulin.
• Additionally, the therapeutic use of beta-adrenergic blocking agents in some patients may contribute to the blunting of lipolysis, further suppressing ketone body formation.

Masking of Hypovolemia by Hypertonicity

• The massive volume depletion in HHS presents a unique clinical challenge because it is frequently masked by the patient's underlying obesity and the extreme hypertonicity of the intravascular space.
• Hypertonicity draws water from the intracellular fluid compartment into the extracellular and intravascular spaces, artificially preserving the circulating blood volume and blood pressure until the dehydration becomes catastrophically severe.
• Consequently, despite profound total body water and electrolyte depletion, the classic physical signs of severe dehydration (such as poor skin turgor or delayed capillary refill) may be less evident on initial clinical examination.

Clinical Manifestations

Neurological and Systemic Signs

• The clinical picture is dominated by severe depression of the sensorium, which correlates closely and directly with the degree of serum hyperosmolarity.
• Patients frequently present in a frank coma or exhibit severe obtundation, confusion, and lethargy.
• Various focal and generalized neurological signs are hallmark features of HHS and may include grand mal seizures, hemiparesis, hyperthermia, and positive Babinski reflexes.
• Unlike patients with DKA, who characteristically present with Kussmaul respirations (deep, sighing breathing) driven by severe ketoacidosis, respirations in patients with isolated HHS are typically shallow.
• However, if profound hypoperfusion and shock lead to coexistent lactic acidosis, secondary Kussmaul breathing may be observed.

Cardiovascular and Thromboembolic Manifestations

• The extreme dehydration leads to severe hemoconcentration and hyperviscosity of the blood.
• This hyperviscous state creates a highly prothrombotic environment, strongly predisposing the patient to life-threatening cerebral arterial thromboses and deep venous thromboses before and during the initial phases of therapy.
• Cardiovascular collapse, marked by extreme tachycardia and eventual hypotension, occurs late in the disease process once the intracellular fluid reservoir is exhausted and the intravascular volume can no longer be maintained by hypertonicity.

Diagnostic Evaluation and Laboratory Investigations

Initial Biochemical Assessment

• The initial diagnosis relies on a comprehensive metabolic panel demonstrating glucose levels consistently exceeding 600 mg/dL (33.3 mmol/L), frequently rising above 800 mg/dL or even 1000 mg/dL.
• Serum electrolytes reveal extreme deficits in total body potassium, magnesium, and phosphate, resulting from prolonged osmotic diuresis, though initial serum concentrations may appear paradoxically normal due to hemoconcentration and fluid shifts.
• Venous blood gas analysis confirms the absence of severe ketoacidosis (pH > 7.25, bicarbonate > 15 mmol/L), though a mild non-anion gap metabolic acidosis or a lactic acidosis secondary to poor tissue perfusion may be present.
• Urine testing will demonstrate massive glycosuria with absent or trace ketones.

Calculation of Serum Osmolality and Corrected Sodium

• The severity of the condition is tracked by calculating the effective serum osmolality, utilizing the formula: Effective Osmolality (mOsm/kg) = 2 × [measured Na] + [glucose in mmol/L].
• Because extreme hyperglycemia artificially lowers the measured serum sodium by drawing free water into the vasculature (pseudohyponatremia), the "corrected sodium" must be calculated to accurately gauge the true sodium and water deficit.
• The corrected sodium is calculated as: Measured Na + 1.6 × ([Glucose in mg/dL - 100] / 100).
• In HHS, the calculated effective serum osmolality routinely exceeds 320 mOsm/kg, and is frequently 350 mOsm/kg or greater.

Management of Hyperosmolar Hyperglycemic Syndrome

1. Fluid Resuscitation and Deficit Replacement

• The paramount and immediate goal of initial therapy in HHS is the rapid repletion of the profoundly depleted vascular volume to reverse hypovolemic shock, restore normal renal perfusion, and prevent ischemic organ damage.
• Due to the massive fluid losses (estimated at 12% to 15% of total body weight), the rate and volume of fluid replacement in HHS must be significantly more aggressive than the protocols utilized for typical DKA.
• Initial resuscitation strictly requires an intravenous bolus of 20 mL/kg (or more) of isotonic saline (0.9% NaCl).
• Additional rapid boluses of 0.9% NaCl must be administered sequentially if the patient exhibits persistent tachycardia, poor peripheral perfusion, or hemodynamic instability.
• Following the initial stabilization of circulating volume, the remaining massive fluid deficit is replaced over a prolonged period of 24 to 48 hours utilizing 0.45% to 0.75% NaCl.
• During this replacement phase, decreasing serum osmolality (caused by the renal clearance of glucose) will force water back out of the intravascular space into the intracellular compartment; if fluid replacement is not maintained at a high rate, the intravascular volume will collapse rapidly.
• The choice of intravenous fluid tonicity (0.45% vs. 0.9% NaCl) is continuously titrated to achieve a very slow, gradual decline in both the corrected serum sodium concentration and the effective serum osmolality.
• A target decline rate of 0.5 mmol/L per hour for the corrected serum sodium is recommended.
• Failure of the corrected serum sodium to decline during treatment is a grave prognostic sign associated with high mortality, and may serve as a clinical indication for emergency hemodialysis.
• Once the serum glucose concentration declines and approaches 300 mg/dL (16.7 mmol/L), the hydrating fluid must be changed to incorporate 5% dextrose (e.g., 5% dextrose in 0.45% NaCl). This prevents rapid drops in osmolality and avoids iatrogenic hypoglycemia while allowing for continued fluid and electrolyte correction.
• Unlike in DKA protocols, it is explicitly recommended in HHS to continuously replace ongoing urinary losses volume-for-volume with intravenous fluids, matching the sodium content to the high urinary output if circulatory volume remains a concern.

2. Insulin Therapy Protocol

• The initiation of insulin therapy in HHS is fundamentally different and significantly delayed compared to the management of DKA.
• Because insulin drives glucose and water out of the intravascular space and into the cells, premature administration of insulin before adequate fluid resuscitation can precipitate catastrophic cardiovascular collapse, irreversible shock, and acute venous thrombosis due to sudden hemoconcentration.
• Aggressive fluid administration alone will cause a precipitous decline in serum glucose concentrations (typically 75 to 100 mg/dL per hour) purely through dilution and the restoration of renal perfusion, which allows for massive urinary glucose excretion.
• Continuous intravenous insulin infusion should be initiated only when the serum glucose concentration ceases to decline at a rate of at least 50 mg/dL (3 mmol/L) per hour with fluid administration alone.
• When indicated, insulin is administered as a continuous intravenous infusion at a very low starting dose of 0.025 to 0.05 Units/kg/hour.
• Intravenous insulin boluses are strictly contraindicated in HHS.
• The insulin infusion rate is carefully titrated to achieve a controlled, slow decrease in serum glucose concentration of approximately 50 to 75 mg/dL (3 to 4 mmol/L) per hour.

3. Electrolyte Management

• Potassium: Patients with HHS suffer from extreme total body potassium deficits due to prolonged osmotic diuresis. Potassium replacement (typically at a concentration of 40 mmol/L in the IV fluids) must be initiated immediately as soon as the serum potassium concentration falls within the normal range and adequate urine output (renal function) is definitively established. Higher rates of potassium infusion may be required once insulin therapy is started, as insulin rapidly drives potassium intracellularly, posing a severe risk of life-threatening arrhythmias. Serum potassium and continuous electrocardiographic monitoring must be performed every 2 to 3 hours, or hourly if severe hypokalemia is present.
• Phosphate: Severe hypophosphatemia is common and can precipitate deadly complications including rhabdomyolysis, muscle weakness, diaphragmatic paralysis, and hemolytic uremia. Phosphate is rigorously replaced using a 50:50 mixture of potassium phosphate and another potassium salt (e.g., potassium chloride or potassium acetate) in the intravenous fluids. This mixed approach provides adequate phosphate while mitigating the risk of inducing severe iatrogenic hypocalcemia, necessitating serum phosphate measurements every 3 to 4 hours.
• Magnesium: Significant magnesium deficits are frequently observed in HHS. If the patient develops severe symptomatic hypomagnesemia or concurrent hypocalcemia during therapy, intravenous magnesium replacement is indicated at a dose of 25 to 50 mg/kg per dose, administered over 4 to 6 hours for 3 to 4 doses.
• Bicarbonate: The administration of sodium bicarbonate is absolutely contraindicated in the management of HHS. It significantly exacerbates the risk of profound hypokalemia and can severely impair tissue oxygen delivery by altering the hemoglobin-oxygen dissociation curve.

Complications of HHS and Specific Interventions

Venous Thrombosis

• Due to extreme hyperviscosity and hemoconcentration, deep venous thrombosis is a highly common and perilous complication, particularly associated with the use of central venous catheters.
• While routine prophylactic use of low-dose heparin is not universally recommended in pediatric patients due to lack of outcome data, therapeutic or prophylactic heparinization must be strongly considered for children who require central venous catheters for access or hemodynamic monitoring and who are expected to remain immobile for more than 24 to 48 hours.

Rhabdomyolysis

• The combination of severe hyperosmolality, hypoperfusion, and hypophosphatemia frequently triggers rhabdomyolysis in children with HHS.
• This manifests clinically as profound myalgia, severe muscle weakness, and dark urine, ultimately resulting in acute oliguric renal failure, life-threatening hyperkalemia, severe hypocalcemia, and muscle swelling that can progress to compartment syndrome.
• Serum creatine kinase (CK) concentrations must be monitored meticulously every 2 to 3 hours to ensure early detection and prompt aggressive fluid management.

Malignant Hyperthermia-Like Syndrome

• A rare but highly lethal complication observed in children presenting with HHS is a clinical syndrome mimicking malignant hyperthermia.
• This syndrome presents with a rapidly escalating high fever associated with a dramatic rise in creatine kinase concentrations and severe muscle rigidity.
• If this syndrome is suspected, emergency treatment with intravenous dantrolene is indicated. Dantrolene acts by reducing the release of calcium from the sarcoplasmic reticulum, thereby stabilizing calcium metabolism within the crashing muscle cells. Despite intervention, mortality remains exceptionally high.

Cerebral Edema

• In stark contrast to pediatric Diabetic Ketoacidosis (DKA), where cerebral edema is the leading cause of mortality, clinically significant cerebral edema is exceedingly rare during the treatment of HHS.
• In a comprehensive 2010 literature review analyzing 96 pediatric cases of HHS (which included 32 deaths), only a single instance of cerebral edema was documented.
• Because altered mental status is a baseline feature of the hyperosmolar state (typically occurring when osmolality exceeds 330 mOsm/kg), clinical improvement in sensorium should be expected as osmolality decreases.
• Therefore, any secondary decline in mental status or neurological deterioration after the hyperosmolality has begun to improve with treatment is highly unusual for HHS and must be urgently investigated with cranial imaging to rule out intracranial hemorrhage or major thromboembolic stroke.

Management of Mixed HHS and DKA

• Occasionally, patients will present with a mixed clinical picture encompassing the extreme hyperosmolality (>320 mOsm/kg) and severe hyperglycemia (>600 mg/dL) of HHS, combined with the severe acidosis (pH < 7.3) and significant ketonemia characteristic of classic DKA.
• The therapeutic approach to a mixed presentation mandates a careful hybrid protocol that addresses the life-threatening risks of both extreme volume depletion and severe acidosis.
• Because of the extreme fluid deficits, the rate of intravenous fluid and electrolyte administration must exceed the standard rates recommended for isolated DKA to prevent cardiovascular collapse.
• While insulin is absolutely essential to arrest hepatic ketogenesis and resolve the severe acidosis, its initiation must still be deferred until after the patient has received substantial initial fluid boluses and the peripheral circulation is firmly stabilized.
• Once hemodynamic stability is achieved, continuous intravenous insulin is initiated earlier than it would be in pure HHS, utilizing a rate between 0.025 to 0.05 Units/kg/hour to clear the ketoacids while carefully monitoring the rate of glucose decline.